A new imaging test for people on HER2 cancer therapy
Part of Cancer, Digestive system, Skin clinical trials.
This study tests a new imaging drug called [68Ga]Ga-ABY-025 to see how well it shows HER2-positive tumors in people who are about to start or have just started HER2-targeted cancer therapy. It may help doctors see if the treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- Your cancer must be advanced or spread and your doctor plans to treat you with HER2-targeted therapy (or you have started it and had no more than 6 cycles)
- A previous biopsy or blood test must show your cancer is HER2-positive (certain breast cancers that are HER2-low also qualify)
- You must have tumors that can be seen on a CT, PET, or MRI scan, and at least one measurable tumor must be outside the liver
- You must be able to lie flat for 30 minutes for an imaging scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new approach that first uses a special scan to find cancer cells that have a specific marker, then delivers targeted radiation to those cells. It is designed for people with advanced solid tumors that have spread and stopped responding to standard treatments.
This study tests a new radioactive tracer called [18F]NOTA-ABY030 to see if it's safe for people with head and neck cancer that may have spread. The tracer lights up cancer cells on a PET scan, helping doctors find tumors more clearly.
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
This trial uses a special imaging scan to see if your cancer has HER2 on its surface, which could help decide if HER2-targeted treatment might work for you. It's for people with metastatic breast cancer or other solid tumors that have spread.
This trial tests a new radioactive drug, [177Lu]Lu-ABY-271, to see how safe it is and where it goes in the body. It is for people with HER2-positive breast cancer that has spread and cannot be removed by surgery.
This study tests a new imaging method (18F-HER2 Affibody PET) to find HER2 protein in breast cancer cells. It may help doctors see which patients might benefit from HER2-targeted treatments.
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.